Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alectinib vs Crizotinib in Treatment-Naive ALK-Positive Advanced NSCLC
NCT02075840Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2014
- Primary completion
- Feb 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 29
01
Overview
A Phase 3 trial of alectinib in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Aug 2014; status: completed.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02075840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02075840.